TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

313 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

134 studies on the map

Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesInflammation and Depression in People With HIV — Grady Memorial Hospital, AtlantaThe Role of mGluR5 in CBT-I — Stony Brook University: Dept of Psychiatry, Stony BrookEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin5-HTP and Creatine for Depression R33 Phase — University of Utah Department of Psychiatry, Salt Lake CityAlpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response — Yale University, New HavenAutologous Stem Cell Transplant for Crohn's Disease — Icahn School of Medicine at Mount Sinai, New YorkPhase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments — Domino's Farms, Ann ArborVirtual tES Device Treatment for Parkinson's Disease Motor Symptoms — U LLC Headquarters, ClevelandA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamIntravenous Ketamine for Treatment-Resistant Depression — Mayo Clinic in Rochester, RochesterClinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease — Phoenix Children's Hospital, PhoenixStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenStudy of ALTO-300 in MDD — Site 200, PhoenixPersonalized Brain Stimulation to Treat Chronic Concussive Symptoms — UCLA, Westwood, Los AngelesClinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis — Johns Hopkins, BaltimoreKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CitySerotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures — Wake Forest University Health Sciences, Winston-SalemFeasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department — University of Kansas Strawberry Hill Campus, Kansas CityA Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease — Banner Sun Health Research Institute, Sun CityA Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery — University of Kentucky, LexingtonDopaminergic Therapy for Anhedonia - 2 — Emory University Hospital, AtlantaDouble-blind, Placebo-controlled Study in Adults With Major Depressive Disorder — Collaborative Neuroscience Network, Garden GroveEffects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression — Laureate Institute for Brain Research, TulsaACT for Individuals With MNCD and Their Care Partners — Texas Tech University Plaza Building, LubbockEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanRCT of Psilocybin-assisted CBT for Depression — UCLA Semel Institute, Los AngelesACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamA Study of Buntanetap in Participants With PD — University of Alabama at Birmingham, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamIdentifying and Treating Depression in the Orthopaedic Trauma Population — Wake Forest University Health Sciences, Winston-SalemA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) — Digestive Health Specialsits, DothanPsilocybin rTMS for Treatment Resistant Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleCognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Massachusetts General Hospital, BostonStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis — GI Alliance, Sun CitySub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceAllopregnanolone (Zuranolone) in Post-stroke Depression — Duke South Neurology Clinic 1L, DurhamAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Erick H. Alayo Medical Corporation - Gastro SB Clinic, Chula VistaA Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) — Woodholme Gastroenterology Associates, Glen BurnieA Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease — Barrow Neurological Institute, PhoenixLeveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City — Washington University School of Medicine, St LouisStratified Pharmacological Approaches for Regulating Circuit-Level Effects — Stanford University, Palo AltoDBS for Depression — Zucker Hillside Hospital, QueensAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaLY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Valleywise Health Medical Center, PhoenixAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab — National Institutes of Health Clinical Center, BethesdaAdjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression — The University of Texas Health Science Center at Houston, HoustonStudy of DISC-0974-201 in Participants With IBD and Anemia — One of a Kind Clinical Research Center, LLC, ScottsdaleSelenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies — Northwestern University, ChicagoA Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis — Investigational Site Number: 8400009, EscondidoA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease — Mayo Clinic in Arizona - Scottsdale, ScottsdaleNeutralizing Interleukin (IL)-6 — Icahn School of Medicine at Mount Sinai, New YorkAmitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease — University of Michigan, Ann ArborDetermining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiRegulation of Affect and Physiology in Depression — University of Southern California, Los AngelesTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdaleA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, DurhamA Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) — Clinnova Research ( Site 1042), AnaheimRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaSlow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II — Washington University School of Medicine/Barnes-Jewish Hospital, St LouisPharmacologic Augmentation of TMS for Depression With D-serine — McLean Hospital, BelmontApimostinel + Automated Neurocognitive Training for Depression — Western Psychiatric Institute and Clinic, PittsburghImaging Depression in Parkinson's Disease — Yale University, New HavenA Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease — Collaborative Neuroscience Network - CNS, Los AlamitosKetamine for Veterans With Parkinson's Disease — San Francisco VA Medical Center, San Francisco, CA, San FranciscoPsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy — MD Anderson Cancer Center, HoustonNeural Response to Inflammatory Challenge in Major Depressive Disorder — Laureate Institute for Brain Research, TulsaKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborSAD Study in Patients With Parkinson's Disease and Motor Fluctuations — Rocky Mountain Clinical Research, EnglewoodTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonTreatment of UC With Novel Therapeutics — Brigham and Women's Hospital, Chestnut HillNeural Circuit Effects of Ketamine in Depression — Icahn School of Medicine at Mount Sinai, New YorkStudy of Novel Therapeutics for Acute Remedy of Colitis — Brigham and Women's Hospital, Chestnut HillEarly Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging) — Institute for Neurodegenerative Disorders, New HavenA Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Clinical Research Site, BellflowerOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenAquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation — University of Michigan, Ann ArborPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonEfficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease — IMC Gulf Coast Gastroenterology, PC, FairhopeA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease — United Medical Doctors, MurrietaPsilocybin-Assisted Therapy for Intergenerational Trauma — The Parsons Research Center for Psychedelic Healing, New YorkAβ Dynamics in LLMD — NYU Langone Health, New YorkCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanCortical Electrophysiology of Response Inhibition in Parkinson's Disease — Emory University Hospital, AtlantaTraining Reward Responsiveness Through Virtual Reality — University of California, Los Angeles, Los AngelesA Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease — Investigational Site Number: 8400024, TucsonEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandVECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease — TLC Clinical Research Inc - Los Angeles, Los AngelesGene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisEvaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression — Laureate Institute for Brain Research, TulsaA Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis — Arkansas Children's (IP Address), Little RockAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisComputerized Cognitive Behavioral Therapies for Suicide Prevention and Depression — Eastern Colorado Health Care System, AuroraCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraInvestigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression — National Institutes of Health Clinical Center, BethesdaPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoUpadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis — University of Michigan, Ann ArborMoving Beyond Inflammation as a Therapeutic Target for Crohn's Disease — Cedars-Sinai Medical Center, Beverly HillsEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Gastro Care Institute, LancasterA Pilot Study of In-lab Dynamic Standing in Parkinson's Disease — Domino's Farms, Ann ArborLow Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy — Pine Rest Christian Mental Health Services, Grand RapidsFirst-in-Human Single and Multiple Dose of HL-400 — Pharmaron CPC, Inc., BaltimoreOpen-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD — Digestive & Liver Center of Florida, OrlandoA Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) — Mayo Clinic, PhoenixModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamLow-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease — Quest Research Institute, Farmington HillsALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New YorkA Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis — Site 024, Canoga ParkUsing taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease — Wellness, Health and Research Facility at UAB, BirminghamA Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease — Gastro Care Institute, LancasterCannabidiol and Older Adult Cannabis Users — University of Colorado at Boulder, BoulderNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonA Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting — Gastro Health Research- St. Vincents East, BirminghamPyridostigmine for the Treatment of Constipation in Parkinson Disease — University of Vermont Medical Center, BurlingtonFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer — Ohio State University Comprehensive Cancer Center, ColumbusPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityPsilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder — Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New YorkR-3750 in Patients With Mild to Moderate Ulcerative Colitis — Amicis Research Center, ValenciaThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — VA Connecticut Healthcare System, West HavenEnrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients. — UPMC Presbyterian Hospital, PittsburghA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, Chino

Showing the 150 nearest — narrow your filters for fewer, closer studies.